TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28107198

Group type: EXPERIMENTAL
Intervention: Rabbit ATG
Number of subjects: 1089

Group type: COMPARATOR
Intervention: Horse ATG
Number of subjects: 1089
Study: 26115618

Group type: EXPERIMENTAL
Intervention: Baseline serum adiponectin (mean 14.3 ± 6.6 μg/ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Baseline urine adiponectin:creatinine (Uadp/cr) (mean 126.8 ± 178.9 μg/ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Proteinuria, hypoalbuminemia, and hyperlipidemia
Number of subjects: 60
Study: 23639045

Group type: EXPERIMENTAL
Intervention: 10 mg lenalidomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 mg lenalidomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: 400 mg moxifloxacin (positive control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21877670

Group type: EXPERIMENTAL
Intervention: 10-week worksite physical activity intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study: 19803566

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Treatment-as-usual (control)
Number of subjects: 102
Study: 18022084

Group type: EXPERIMENTAL
Intervention: Assist device therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heart failure
Number of subjects: 0
Study: 14743912

Group type: EXPERIMENTAL
Intervention: 3DAC MR axonography
Number of subjects: 20
Study: 11561270

Group type: EXPERIMENTAL
Intervention: Intrathecal mixture containing bupivacaine 0.125% and sufentanil 0.75 microg/mL with epinephrine 1.25 microg/mL
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intrathecal mixture containing bupivacaine 0.125% and sufentanil 0.75 microg/mL without epinephrine
Number of subjects: 45
Study: 9541845

Group type: EXPERIMENTAL
Intervention: Percutaneous vascular surgery (PVS)
Number of subjects: 590
Study: 8146894

Group type: EXPERIMENTAL
Intervention: GM‐CSF (250 micrograms/m2 x 21 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no GM‐CSF)
Number of subjects: 16
Study: 3409630

Group type: EXPERIMENTAL
Intervention: Ethanol (40 g) plus fat (70 g)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Fat only
Number of subjects: 9
Study: 30989377

Group type: EXPERIMENTAL
Intervention: Prediabetes group (HbA1c between 5.7 and 6.4%)
Number of subjects: 4459

Group type: COMPARATOR
Intervention: Non-prediabetes group
Number of subjects: 4459

Group type: EXPERIMENTAL
Intervention: Overall population analysis
Number of subjects: 4459
Study: 28480078

Group type: EXPERIMENTAL
Intervention: Web-based only (WO)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Web-based supplemented by peer-led discussion (WD)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Web-based supplemented by professional email counseling (WE)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 301
Study: 25609219

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose followed by 75 mg maintenance dose)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Clopidogrel with dronedarone (moderate CYP3A4 inhibitor)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Predicted AUC0-24 from PBPK model
Number of subjects: 4
Study: 22642341

Group type: EXPERIMENTAL
Intervention: Kind Acts
Number of subjects: 142

Group type: COMPARATOR
Intervention: Behavioral Experiments
Number of subjects: 142

Group type: COMPARATOR
Intervention: Activity Monitoring
Number of subjects: 142
Study: 21460029

Group type: EXPERIMENTAL
Intervention: Velocity-encoded (VE) MR imaging
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Tissue Doppler imaging
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 33
Study: 18299653

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 1.5 mg/kg (Group L2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Beclomethasone inhaler 50 microg (Group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous normal saline (Group C)
Number of subjects: 120
Study: 16517328

Group type: EXPERIMENTAL
Intervention: Fentanyl (0.5‐microg/kg bolus, 0.5 microg.kg(‐1).h(‐1), n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dexmedetomidine (0.5‐microg/kg bolus, 0.4 microg.kg(‐1).h(‐1), n = 10)
Number of subjects: 20
Study: 12740541

Group type: EXPERIMENTAL
Intervention: Cervitec varnish
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 85
Study: 11097662

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% with epinephrine 0.5 microg/kg (n = 21)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% with epinephrine 0.75 microg/kg (n = 21)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Lidocaine 1% with saline (n = 19)
Number of subjects: 61
Study: 9088816

Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg, three times, at 6 h intervals (23 patients)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg, twice, at 12 h intervals (25 patients)
Number of subjects: 73

Group type: COMPARATOR
Intervention: 0.9% saline three times, at 6 h intervals (25 patients)
Number of subjects: 73
Study: 1492531

Group type: EXPERIMENTAL
Intervention: Spherically curved stimuli with varying curvatures and contact forces
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Spherically curved stimuli with varying curvatures
Number of subjects: 28
Study: 3884025

Group type: EXPERIMENTAL
Intervention: Diazepam 0.25 mg kg‐1 by mouth
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31331296

Group type: EXPERIMENTAL
Intervention: Ultrasound during prenatal care
Number of subjects: 18640
Study: 29391311

Group type: EXPERIMENTAL
Intervention: Group A (within 2 weeks from education to colonoscopy)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Group B (more than 2 weeks from education to colonoscopy)
Number of subjects: 130
Study: 27814857

Group type: EXPERIMENTAL
Intervention: Positional Release Therapy (PRT) in shortened position
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham control in neutral position
Number of subjects: 28
Study: 24936899

Group type: EXPERIMENTAL
Intervention: G-trainer
Number of subjects: 12

Group type: COMPARATOR
Intervention: CompuTrainer (stationary cycling)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Static stretching
Number of subjects: 12
Study: 22650127

Group type: EXPERIMENTAL
Intervention: Comprehensive treatment group (cotton sheet moxibustion combined with plum-blossom-needle tapping therapy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Western medication group (Acyclovir ointment, Valaciclovir Hydrochloride tablets, Vitamin B1)
Number of subjects: 120
Study: 20204256

Group type: EXPERIMENTAL
Intervention: Inulin enriched cookie
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control cookie
Number of subjects: 34
Study: 18363746

Group type: EXPERIMENTAL
Intervention: Polyphenon E 15% ointment
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Polyphenon E 10% ointment
Number of subjects: 503

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Polyphenon E 15% and 10% ointment
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Polyphenon E ointments
Number of subjects: 503
Study: 16131636

Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI) services
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual services (Control)
Number of subjects: 96
Study: 12203663

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 150 IU/kg, 3 times a week for 8 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 34
Study: 11677109

Group type: EXPERIMENTAL
Intervention: Gemcitabine at 1000 mg/m2 days 1 and 8 with carboplatin AUC 4.5
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gemcitabine at 1000 mg/m2 days 1 and 8 with carboplatin AUC 5
Number of subjects: 16
Study: 9043841

Group type: EXPERIMENTAL
Intervention: Pre-hospital thrombolytic treatment followed by placebo in hospital (pre-hospital group)
Number of subjects: 5469

Group type: COMPARATOR
Intervention: Pre-hospital thrombolytic treatment (hospital group)
Number of subjects: 5469
Study: 7971289

Group type: EXPERIMENTAL
Intervention: 18FDG uptake in grade 2- and 3-meningiomas
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 18FDG uptake in tumors of high cellularity
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 18FDG uptake in meningiomas with elevated Ki-67 proliferation index (above 2%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 18FDG uptake in meningiomas with pronounced chromosomal aberrations
Number of subjects: 60
Study: 2485056

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg once daily, doubled if BP uncontrolled after 4 weeks.
Number of subjects: 174

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg once daily, doubled if BP uncontrolled after 4 weeks.
Number of subjects: 174
Study: 31353846

Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB) program consisting of seven educational sessions
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB) program
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 84
Study: 29603851

Group type: EXPERIMENTAL
Intervention: 0.75 mg/d of atrasentan
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 1.25 mg/d of atrasentan
Number of subjects: 161
Study: 28520838

Group type: EXPERIMENTAL
Intervention: PREPARE website plus an easy-to-read advance directive (AD)
Number of subjects: 414

Group type: COMPARATOR
Intervention: AD alone
Number of subjects: 414
Study: 25935897

Group type: EXPERIMENTAL
Intervention: Experimental condition using the volitional help sheet to link emotional eating triggers with strategies for change
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control condition identifying emotional eating triggers and strategies for change (volitional help sheet)
Number of subjects: 240
Study: 23329850

Group type: EXPERIMENTAL
Intervention: Live attenuated tetravalent dengue vaccine (LATV)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 21465320

Group type: EXPERIMENTAL
Intervention: Boussignac CPAP mask
Number of subjects: 81

Group type: COMPARATOR
Intervention: Venturi mask
Number of subjects: 81
Study: 19115644

Group type: EXPERIMENTAL
Intervention: Sevoflurane/remifentanil anaesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propofol/remifentanil anaesthesia
Number of subjects: 20
Study: 17186795

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate spray 0.05%
Number of subjects: 120

Group type: COMPARATOR
Intervention: Vehicle spray
Number of subjects: 120
Study: 12962529

Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day for 12 months (6 months double-blind and 6 months open-label)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Galantamine 24 mg/day for 6 months (after switching from placebo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 6 months (double-blind) followed by galantamine 24 mg/day for 6 months (open-label)
Number of subjects: 0
Study: 10831024

Group type: EXPERIMENTAL
Intervention: Divalproex sodium (target serum concentration of 75 microg/mL for 2 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (replaced divalproex during the third week)
Number of subjects: 12
Study: 9381056

Group type: EXPERIMENTAL
Intervention: Sera from RBD patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sera from control group
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sera from patients with paraneoplastic anti-Hu and anti-Ri antibodies
Number of subjects: 10
Study: 8417457

Group type: EXPERIMENTAL
Intervention: Modified-modified Schöber technique
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Double inclinometer method
Number of subjects: 15
Study: 31742897

Group type: EXPERIMENTAL
Intervention: Image-guided radiotherapy (IGRT)
Number of subjects: 590

Group type: COMPARATOR
Intervention: Non-image-guided radiotherapy (non-IGRT)
Number of subjects: 590
Study: 29257943

Group type: EXPERIMENTAL
Intervention: 4% articaine 1.8 mL as a buccal injection and 0.2 mL as a palatal injection
Number of subjects: 84

Group type: COMPARATOR
Intervention: 4% articaine 1.8 mL plus normal saline 0.2 mL as a palatal injection
Number of subjects: 84

Group type: COMPARATOR
Intervention: 2% lidocaine 3.6 mL plus normal saline 0.2 mL as a palatal injection
Number of subjects: 84
Study: 28271424

Group type: EXPERIMENTAL
Intervention: Lifestyle Balance (LB)
Number of subjects: 1246

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1246
Study: 25825422

Group type: EXPERIMENTAL
Intervention: 10 units of BTX‐A
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 20 units of BTX‐A
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 42
Study: 22851003

Group type: EXPERIMENTAL
Intervention: Electronic version of the SDI-21
Number of subjects: 111

Group type: COMPARATOR
Intervention: Paper version of the SDI-21
Number of subjects: 111
Study: 22026393

Group type: EXPERIMENTAL
Intervention: Statins (including atorvastatin, pravastatin, rosuvastatin, simvastatin)
Number of subjects: 32311

Group type: EXPERIMENTAL
Intervention: Statins for primary prevention
Number of subjects: 32311

Group type: EXPERIMENTAL
Intervention: Statins for secondary prevention
Number of subjects: 32311

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10-40 mg/day)
Number of subjects: 32311

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 32311
Study: 18303246

Group type: EXPERIMENTAL
Intervention: Heparin administration within 3 hours from stroke onset
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin administration within 48 hours from stroke onset
Number of subjects: 0
Study: 17154093

Group type: EXPERIMENTAL
Intervention: External irradiation (20 Gy total dose delivered in 2 Gy daily fractions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: External irradiation (as monotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined therapy (orbital radiation with high-dose intravenous steroid pulse treatment)
Number of subjects: 0
Study: 12947992

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous immunotherapy (SIT)
Number of subjects: 0
Study: 10753020

Group type: EXPERIMENTAL
Intervention: Atopy patch test (APT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Oral food challenges with allergen
Number of subjects: 75

Group type: COMPARATOR
Intervention: Oral food challenges with placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Specific IgE in serum
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Skin prick test
Number of subjects: 75
Study: 9190240

Group type: EXPERIMENTAL
Intervention: Moderate asthma (II group)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Severe, corticosteroid-dependent asthma (III group)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 3
Study: 1558898

Group type: EXPERIMENTAL
Intervention: Fenfluramine hydrochloride (60 mg/os)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 3891348

Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg b.i.d. administered orally from the first postoperative day till angiography)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Acenocoumarol (initiated on the second to third postoperative day)
Number of subjects: 149
Study: 31923189

Group type: EXPERIMENTAL
Intervention: SMART Eating intervention
Number of subjects: 732

Group type: COMPARATOR
Intervention: Comparison group (pamphlets on nutrition education)
Number of subjects: 732
Study: 30190206

Group type: EXPERIMENTAL
Intervention: FIREHAWK stent
Number of subjects: 1653

Group type: COMPARATOR
Intervention: XIENCE stent
Number of subjects: 1653
Study: 26525553

Group type: EXPERIMENTAL
Intervention: BG cream with 2-week follow-up (BG1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: BG cream with 8-week follow-up (BG2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MTA with 2-week follow-up (MTA1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MTA with 8-week follow-up (MTA2)
Number of subjects: 36
Study: 24332263

Group type: EXPERIMENTAL
Intervention: RW-SAIL (standardized glycerinated short ragweed sublingual allergen immunotherapy liquid)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study: 22739069

Group type: COMPARATOR
Intervention: Physical activity (measured by activity monitor and questionnaire)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Self-reported perception of physical and sedentary activities
Number of subjects: 35

Group type: COMPARATOR
Intervention: Maximal cardiopulmonary exercise test (CPET)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 35
Study: 21287468

Group type: EXPERIMENTAL
Intervention: Conferences utilizing small-group discussions
Number of subjects: 170

Group type: COMPARATOR
Intervention: Traditional conference method (control)
Number of subjects: 170
Study: 16729206

Group type: EXPERIMENTAL
Intervention: Bifurcated trial format
Number of subjects: 59

Group type: COMPARATOR
Intervention: Unitary trial format
Number of subjects: 59
Study: 15523350

Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment
Number of subjects: 167

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 167
Study: 11422545

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy with cognitive counter conditioning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy without cognitive counter conditioning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list controls
Number of subjects: 0
Study: 9413873

Group type: EXPERIMENTAL
Intervention: Methylcobalamin (3 mg/day) for 4 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 50
Study: 8492040

Group type: EXPERIMENTAL
Intervention: Stapled ileocolonic anastomosis (side-to-side with GIA+TA devices)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Manual anastomosis (84 interrupted end‐to‐end, 77 continuous end‐to‐end, 82 interrupted end‐to‐side, 91 continuous end‐to‐side)
Number of subjects: 440
Study: 3329531

Group type: EXPERIMENTAL
Intervention: Oral flucloxacillin and nebulized aminoglycoside
Number of subjects: 6

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 6
Study: 30556429

Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo insoles
Number of subjects: 53
Study: 29226626

Group type: COMPARATOR
Intervention: GSK2982772 (0.1-120 mg single ascending doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GSK2982772 (20 mg once daily to 120 mg twice daily for 14 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSK2982772 (20 mg tablets vs capsules)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26474630

Group type: EXPERIMENTAL
Intervention: Shikani optical stylet (SOS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 60
Study: 24427279

Group type: EXPERIMENTAL
Intervention: 400 mg/day DHA from 16 wk gestation to delivery
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 22930173

Group type: EXPERIMENTAL
Intervention: Polypectomy during insertion and withdrawal (Group A)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Polypectomy during withdrawal only (Group B)
Number of subjects: 301
Study: 18952910

Group type: EXPERIMENTAL
Intervention: 40 mg rosuvastatin alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 135 mg ABT‐335 alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of 40 mg rosuvastatin and 135 mg ABT‐335
Number of subjects: 18

Group type: COMPARATOR
Intervention: All 3 regimens
Number of subjects: 18
Study: 17679016

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b 250 microg subcutaneously every other day for 2 years
Number of subjects: 468

Group type: COMPARATOR
Intervention: Delayed treatment (placebo)
Number of subjects: 468
Study: 16250039

Group type: EXPERIMENTAL
Intervention: MTX plus UDCA
Number of subjects: 265

Group type: COMPARATOR
Intervention: UDCA plus placebo
Number of subjects: 265
Study: 12414411

Group type: EXPERIMENTAL
Intervention: Topical ofloxacin 0.3% applied four times daily for 3 days before surgery
Number of subjects: 89

Group type: COMPARATOR
Intervention: Topical ofloxacin 0.3% applied 1 hour before surgery
Number of subjects: 89
Study: 10203198

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression combined with standard physiotherapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard physiotherapy alone (Control)
Number of subjects: 37
Study: 8525170

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 52

Group type: COMPARATOR
Intervention: Ceftazidime-amikacin
Number of subjects: 52
Study: 2156597

Group type: EXPERIMENTAL
Intervention: Ifosfamide (3 g/m2 plus 3 g/m2 of mesna)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Mitomycin (8 mg/m2)
Number of subjects: 110

Group type: COMPARATOR
Intervention: MVP arm (Mitomycin plus vindesine and cisplatin)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: IVP arm (Ifosfamide plus vindesine and cisplatin)
Number of subjects: 110
Study: 120538

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentobarbital
Number of subjects: 0
Study: 31791688

Group type: COMPARATOR
Intervention: Weekly paclitaxel 80 mg/m2 and carboplatin AUC5 or AUC6 every 3 weeks (Group 2)
Number of subjects: 1566

Group type: COMPARATOR
Intervention: Weekly paclitaxel 80 mg/m2 and carboplatin AUC2 (Group 3)
Number of subjects: 1566

Group type: EXPERIMENTAL
Intervention: Standard 3-weekly chemotherapy (Group 1)
Number of subjects: 1566
Study: 27758726

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 26289234

Group type: EXPERIMENTAL
Intervention: Redesigned DDI alerts
Number of subjects: 20

Group type: COMPARATOR
Intervention: Original DDI alerts
Number of subjects: 20
Study: 23593478

Group type: EXPERIMENTAL
Intervention: Arousal Stimulation (50-second cold pressor stimulation, immersing the foot in 0-2° C water)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham Control (immersing the foot in room temperature water)
Number of subjects: 68
Study: 21880911

Group type: EXPERIMENTAL
Intervention: CRF(1) antagonist GW876008
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0